Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP)

Date

2014-11
Language
American English

Embargo Lift Date

Committee Members

Degree

Degree Year

Department

Grantor

Journal Title

Journal ISSN

Volume Title

Found At

Wiley-Blackwell

Abstract

BACKGROUND: Few studies have measured the ability of interventions to affect declining β-cell function in screen-detected type 2 diabetes. The Early Diabetes Intervention Programme (ClinicalTrials.gov NCT01470937) was a randomized study based on the hypothesis that improving postprandial glucose excursions with acarbose would slow the progression of fasting hyperglycaemia in screen-detected type 2 diabetes. In the Early Diabetes Intervention Programme, the effect of acarbose plus lifestyle advice on progression of fasting hyperglycaemia over a 5-year period was not greater than that of placebo. However, there was an early glucose-lowering effect of the trial. The objective of the current secondary analysis was to describe β-cell function changes in response to glucose lowering. METHODS: Participants were overweight adult subjects with screen-detected type 2 diabetes. β-cell function was measured using hyperglycaemic clamps and oral glucose tolerance testing. The primary outcome was the change in β-cell function from baseline to year 1, the time point where the maximal glucose-lowering effect was seen. RESULTS: At baseline, participants exhibited markedly impaired first-phase insulin response. Despite significant reductions in weight, fasting plasma glucose (PG) and 2-h PG, there was no clinically significant improvement in the first-phase insulin response. Late-phase insulin responses declined despite beneficial glycaemic effects of interventions. CONCLUSIONS: Insulin secretion is already severely impaired in early, screen-detected type 2 diabetes. Effective glucose-lowering intervention with acarbose was not sufficient to improve insulin secretion or halt the decline of β-cell function.

Description

item.page.description.tableofcontents

item.page.relation.haspart

Cite As

Hannon, T. S., Kirkman, Patel, Y. R., Considine, R. V., & Mather, K. J. (2014). Profound Defects in β-Cell Function in Screen-Detected Type 2 Diabetes Are Not Improved with Glucose-Lowering Treatment in the Early Diabetes Prevention Program (EDIP). Diabetes/metabolism Research and Reviews, 30(8), 767–776. http://doi.org/10.1002/dmrr.2553

ISSN

1520-7560

Publisher

Series/Report

Sponsorship

Major

Extent

Identifier

Relation

Journal

Diabetes/Metabolism Research and Reviews

Rights

Publisher Policy

Source

PMC

Alternative Title

Type

Article

Number

Volume

Conference Dates

Conference Host

Conference Location

Conference Name

Conference Panel

Conference Secretariat Location

Version

Author's manuscript

Full Text Available at

This item is under embargo {{howLong}}